287 related articles for article (PubMed ID: 37277530)
21. YAP and TAZ are transcriptional co-activators of AP-1 proteins and STAT3 during breast cellular transformation.
He L; Pratt H; Gao M; Wei F; Weng Z; Struhl K
Elife; 2021 Aug; 10():. PubMed ID: 34463254
[TBL] [Abstract][Full Text] [Related]
22. Convergence of YAP/TAZ, TEAD and TP63 activity is associated with bronchial premalignant severity and progression.
Ning B; Tilston-Lunel AM; Simonetti J; Hicks-Berthet J; Matschulat A; Pfefferkorn R; Spira A; Edwards M; Mazzilli S; Lenburg ME; Beane JE; Varelas X
J Exp Clin Cancer Res; 2023 May; 42(1):116. PubMed ID: 37150829
[TBL] [Abstract][Full Text] [Related]
23. Effect of the acylation of TEAD4 on its interaction with co-activators YAP and TAZ.
Mesrouze Y; Meyerhofer M; Bokhovchuk F; Fontana P; Zimmermann C; Martin T; Delaunay C; Izaac A; Kallen J; Schmelzle T; Erdmann D; Chène P
Protein Sci; 2017 Dec; 26(12):2399-2409. PubMed ID: 28960584
[TBL] [Abstract][Full Text] [Related]
24. Advances of targeting the YAP/TAZ-TEAD complex in the hippo pathway for the treatment of cancers.
Luo M; Xu Y; Chen H; Wu Y; Pang A; Hu J; Dong X; Che J; Yang H
Eur J Med Chem; 2022 Dec; 244():114847. PubMed ID: 36265280
[TBL] [Abstract][Full Text] [Related]
25. β-Catenin Sustains and Is Required for YES-associated Protein Oncogenic Activity in Cholangiocarcinoma.
Zhang Y; Xu H; Cui G; Liang B; Chen X; Ko S; Affo S; Song X; Liao Y; Feng J; Wang P; Wang H; Xu M; Wang J; Pes GM; Ribback S; Zeng Y; Singhi A; Schwabe RF; Monga SP; Evert M; Tang L; Calvisi DF; Chen X
Gastroenterology; 2022 Aug; 163(2):481-494. PubMed ID: 35489428
[TBL] [Abstract][Full Text] [Related]
26. YAP/TAZ-TEAD is a novel transcriptional regulator of genes encoding steroidogenic enzymes in rat granulosa cells and KGN cells.
Mizutani T; Orisaka M; Kawabe S; Morichika R; Uesaka M; Yoshida Y
Mol Cell Endocrinol; 2023 Jan; 559():111808. PubMed ID: 36309205
[TBL] [Abstract][Full Text] [Related]
27. Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth.
Zanconato F; Forcato M; Battilana G; Azzolin L; Quaranta E; Bodega B; Rosato A; Bicciato S; Cordenonsi M; Piccolo S
Nat Cell Biol; 2015 Sep; 17(9):1218-27. PubMed ID: 26258633
[TBL] [Abstract][Full Text] [Related]
28. Leveraging Hot Spots of TEAD-Coregulator Interactions in the Design of Direct Small Molecule Protein-Protein Interaction Disruptors Targeting Hippo Pathway Signaling.
Zhao B; Pobbati AV; Rubin BP; Stauffer S
Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111340
[TBL] [Abstract][Full Text] [Related]
29. YAP/TAZ for cancer therapy: opportunities and challenges (review).
Guo L; Teng L
Int J Oncol; 2015 Apr; 46(4):1444-52. PubMed ID: 25652178
[TBL] [Abstract][Full Text] [Related]
30. Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway.
Jang JW; Kim MK; Bae SC
Small GTPases; 2020 Jul; 11(4):280-288. PubMed ID: 29457552
[TBL] [Abstract][Full Text] [Related]
31. The novel potent TEAD inhibitor, K-975, inhibits YAP1/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma.
Kaneda A; Seike T; Danjo T; Nakajima T; Otsubo N; Yamaguchi D; Tsuji Y; Hamaguchi K; Yasunaga M; Nishiya Y; Suzuki M; Saito JI; Yatsunami R; Nakamura S; Sekido Y; Mori K
Am J Cancer Res; 2020; 10(12):4399-4415. PubMed ID: 33415007
[TBL] [Abstract][Full Text] [Related]
32. The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment.
Santucci M; Vignudelli T; Ferrari S; Mor M; Scalvini L; Bolognesi ML; Uliassi E; Costi MP
J Med Chem; 2015 Jun; 58(12):4857-73. PubMed ID: 25719868
[TBL] [Abstract][Full Text] [Related]
33. New insights into the ambivalent role of YAP/TAZ in human cancers.
Luo J; Deng L; Zou H; Guo Y; Tong T; Huang M; Ling G; Li P
J Exp Clin Cancer Res; 2023 May; 42(1):130. PubMed ID: 37211598
[TBL] [Abstract][Full Text] [Related]
34. The Hippo pathway mediates inhibition of vascular smooth muscle cell proliferation by cAMP.
Kimura TE; Duggirala A; Smith MC; White S; Sala-Newby GB; Newby AC; Bond M
J Mol Cell Cardiol; 2016 Jan; 90():1-10. PubMed ID: 26625714
[TBL] [Abstract][Full Text] [Related]
35. Cysteine S-Glutathionylation Promotes Stability and Activation of the Hippo Downstream Effector Transcriptional Co-activator with PDZ-binding Motif (TAZ).
Gandhirajan RK; Jain M; Walla B; Johnsen M; Bartram MP; Huynh Anh M; Rinschen MM; Benzing T; Schermer B
J Biol Chem; 2016 May; 291(22):11596-607. PubMed ID: 27048650
[TBL] [Abstract][Full Text] [Related]
36. TAZ/YAP fusion proteins: mechanistic insights and therapeutic opportunities.
Garcia K; Gingras AC; Harvey KF; Tanas MR
Trends Cancer; 2022 Dec; 8(12):1033-1045. PubMed ID: 36096997
[TBL] [Abstract][Full Text] [Related]
37. Physiological and pathological roles of the Hippo-YAP/TAZ signaling pathway in liver formation, homeostasis, and tumorigenesis.
Nishina H
Cancer Sci; 2022 Jun; 113(6):1900-1908. PubMed ID: 35349740
[TBL] [Abstract][Full Text] [Related]
38. Yes-associated protein and transcriptional coactivator with PDZ-binding motif as new targets in cardiovascular diseases.
Yu Y; Su X; Qin Q; Hou Y; Zhang X; Zhang H; Jia M; Chen Y
Pharmacol Res; 2020 Sep; 159():105009. PubMed ID: 32553712
[TBL] [Abstract][Full Text] [Related]
39. Establishment of transgenic lines to monitor and manipulate Yap/Taz-Tead activity in zebrafish reveals both evolutionarily conserved and divergent functions of the Hippo pathway.
Miesfeld JB; Link BA
Mech Dev; 2014 Aug; 133():177-88. PubMed ID: 24560909
[TBL] [Abstract][Full Text] [Related]
40. A Division of Labor between YAP and TAZ in Non-Small Cell Lung Cancer.
Shreberk-Shaked M; Dassa B; Sinha S; Di Agostino S; Azuri I; Mukherjee S; Aylon Y; Blandino G; Ruppin E; Oren M
Cancer Res; 2020 Oct; 80(19):4145-4157. PubMed ID: 32816858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
